Toggle Main Menu Toggle Search

Open Access padlockePrints

The Newcastle University research output collection, currently available on ePrints, will shortly be moving to a new open repository platform, Figshare. To prepare for the data migration we have paused adding new content to ePrints, and will resume once the new repository is launched. During this time you will continue to have access to ePrints (but no new content will appear). We will share updates here when available.

Epigenetic repression of the dopamine receptor D4 in pediatric tumors of the central nervous system

Lookup NU author(s): Professor Steven CliffordORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

Epigenetic alterations are common events in cancer. Using a genome wide methylation screen (Restriction Landmark Genomic Scanning-RLGS) we identified the gene for the dopamine receptor D4 (DRD4) as tumor-specific methylated. As DRD4 is involved in early brain development and may thus be involved in developmentally dependent tumors of the CNS in children epigenetic deregulation of DRD4 and its functional consequences were analyzed in vitro. CpG methylation of DRD4 was detected in 18/24 medulloblastomas, 23/29 ependymomas, 6/6 high-grade gliomas, 7/10 CNS PNET and 8/8 cell lines by qCOBRA and bisulfite sequencing. Real-time RT-PCR demonstrated a significantly inferior expression of DRD4 in primary tumors compared to cell lines and non-malignant control tissues. Epigenetic deregulation of DRD4 was analyzed in reexpression experiments and restoration of DRD4 was observed in medulloblastoma (MB) cells treated with 5-Aza-CdR. Reexpression was not accompanied by demethylation of the DRD4 promoter but by a significant decrease of H3K27me3 and of bound enhancer of zeste homologue 2 (EZH2). Knockdown of EZH2 demonstrated DRD4 as a direct target for inhibition by EZH2. Stimulation of reexpressed DRD4 resulted in an activation of ERK1/2. Our analyses thus disclose that DRD4 is epigenetically repressed in CNS tumors of childhood. DRD4 is a direct target of EZH2 in MB cell lines. EZH2 appears to dominate over aberrant DNA methylation in the epigenetic inhibition of DRD4, which eventually leads to inhibition of a DRD4-mediated stimulation of the ERK1/2 kinase pathway.


Publication metadata

Author(s): Unland R, Kerl K, Schlosser S, Farwick N, Plagemann T, Lechtape B, Clifford SC, Kreth JH, Gerss J, Muhlisch J, Richter GHS, Hasselblatt M, Fruhwald MC

Publication type: Article

Publication status: Published

Journal: Journal of Neuro-Oncology

Year: 2014

Volume: 116

Issue: 2

Pages: 237-249

Print publication date: 01/01/2014

ISSN (print): 0167-594X

ISSN (electronic): 1573-7373

Publisher: Springer US

URL: http://dx.doi.org/10.1007/s11060-013-1313-1

DOI: 10.1007/s11060-013-1313-1


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
Astrid-Haugstrup-Sorensen Gedachtnis-Stiftung in the Stifterverband fur die Deutsche Wissenschaft and is part of the Translational Sarcoma Research Network
CD-
Cora Lobscheid-
109062Deutsche Krebshilfe
DRL 01GM0869BMBF
FK 01GM1104BBMBF

Share